Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis

Cancer J. 2020 Mar/Apr;26(2):116-123. doi: 10.1097/PPO.0000000000000437.

Abstract

Oligometastasis represents an intermediate disease stage between localized and widely metastatic cancer. Efficient identification of patients with oligometastasis remains a barrier for accrual on clinical trials of oligometastasis-directed therapy. Here we review the prospect of circulating tumor DNA-based monitoring to promote sensitive, specific, and cost-efficient detection of cancer recurrence during posttreatment surveillance. Thus, an impetus for the development and implementation of clinical-grade circulating tumor DNA assays should be for the positive impact they will have on clinical investigations of oligometastasis-directed therapy.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics
  • Circulating Tumor DNA / blood*
  • Circulating Tumor DNA / genetics
  • Early Detection of Cancer / methods*
  • Humans
  • Neoplasm Metastasis / diagnosis*
  • Neoplasm Metastasis / genetics
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / genetics
  • Neoplasms / diagnosis*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Neoplasms / therapy

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA